Allspring Global Investments’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Allspring Global Investments’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-360,151	Closed	-$6.19M	–	2858
2023 Q1	$6.19M	Sell	360,151 -34,383	-9%	-$696K	0.01%	942
2022 Q4	$7.95M	Sell	394,534 -633	-0.2%	-$13.6K	0.01%	848
2022 Q3	$8.56M	Sell	395,167 -1,785	-0.4%	-$48.8K	0.02%	818
2022 Q2	$11.2M	Sell	396,952 -13,129	-3%	-$348K	0.02%	751
2022 Q1	$18.9M	Sell	410,081 -8,711	-2%	-$470K	0.02%	680
2021 Q4	$35.2M	Buy	+418,792	New	+$32.4M	0.04%	540

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Allspring Global Investments's ZNTL Position: Q2 2023 in Review

Allspring Global Investments sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2023, closing a stake of 360,151 shares — an estimated $6.19M sold.

Allspring Global Investments first reported a position in ZNTL in Q4 2021 and held it in 6 quarters. The position peaked at $35.2M in Q4 2021. 134 funds tracked by Wall St. Rank hold ZNTL as of Q2 2023.

Allspring Global Investments reported no remaining Zentalis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Allspring Global Investments sold 360,151 Zentalis Pharmaceuticals shares in Q2 2023, an estimated $6.19M.
Allspring Global Investments first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Allspring Global Investments's Zentalis Pharmaceuticals position peaked at $35.2M in Q4 2021.
134 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2023.

Based on Allspring Global Investments's 13F filing for Q2 2023, filed 18 Jul 2023.